Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. METHODS: We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. RESULTS: A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P = 0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril-valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril-valsartan group and 379 patients (13.4%) in the ramipril group. CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, NCT02924727.).

Full Text

Duke Authors

Cited Authors

  • Pfeffer, MA; Claggett, B; Lewis, EF; Granger, CB; Køber, L; Maggioni, AP; Mann, DL; McMurray, JJV; Rouleau, J-L; Solomon, SD; Steg, PG; Berwanger, O; Cikes, M; De Pasquale, CG; East, C; Fernandez, A; Jering, K; Landmesser, U; Mehran, R; Merkely, B; Vaghaiwalla Mody, F; Petrie, MC; Petrov, I; Schou, M; Senni, M; Sim, D; van der Meer, P; Lefkowitz, M; Zhou, Y; Gong, J; Braunwald, E; PARADISE-MI Investigators and Committees,

Published Date

  • November 11, 2021

Published In

Volume / Issue

  • 385 / 20

Start / End Page

  • 1845 - 1855

PubMed ID

  • 34758252

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa2104508

Language

  • eng

Conference Location

  • United States